JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
US8202881B2 · kind B2 · utility
10Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 2, 2010 |
| Grant date | Jun 19, 2012 |
| Priority date | — |
| Expiry date | Nov 16, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.